RxDoctor Payments Data

Daniel Rivard, MD

Internal Medicine · Cheyenne, WYNPI 1942475298

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 9 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 7 manufacturers reported payments, led by GSK at 21.7% of the total. 2025 is the largest year on record at $134, 7.1 times the $19 reported in 2021.

$193in general payments, 2019–2025

Across 9 payments — averaging $21.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$42
  • Novo Nordisk$36
  • Lundbeck LLC$29
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$23
  • Amgen$22
  • Exact Sciences$22
  • plus $19 from 1 others

What the payments were for

  • Food & beverage$193100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$193 in reported general payments places this provider in the 70th percentile of 101 internal medicine providers in Wyoming.

See all internal medicine providers in Wyoming

Medicare billing

Part B allowed, 2024
$226,709
Medicare patients
655
Services billed
2,849

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban136$103,338
Dupixent PenDupilumab16$70,621
OzempicSemaglutide67$67,697
TrulicityDulaglutide35$38,245
XareltoRivaroxaban28$22,444
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$22,032
JardianceEmpagliflozin20$21,866
JanuviaSitagliptin Phosphate11$15,554
LinzessLinaclotide18$14,347
FarxigaDapagliflozin Propanediol15$13,086
Breo ElliptaFluticasone/Vilanterol17$11,628
Fluticasone-SalmeterolFluticasone Propion/Salmeterol55$9,860
MyrbetriqMirabegron13$7,927
Gabapentin244$5,099
Lansoprazole17$5,027

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$19$103,338136 claims
Novo NordiskOzempic$36$67,69767 claims
GSKTrelegy Ellipta, Breo Ellipta$42$33,65931 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 101 internal medicine providers in Wyoming.

Other internal medicine in Cheyenne

See the full list for Wyoming

Where these figures come from

Is this you, or does something look wrong? →